1.
Adam Gibb, Craig Jones, Adrian Bloor, Samar Kulkarni, Tim Illidge, Kim Linton, John Radford. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. haematol [Internet]. 2013Mar.31 [cited 2024Jun.13];98(4):611-4. Available from: https://haematologica.org/article/view/6631